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Abstract
Background: Accurate measurement of tumor burden in breast cancer disease is essential to improve the clinical
management of patients. In this study, we evaluate whether the fluctuations in the fraction of PIK3CA mutant allele
correlates with tumor response according to RECIST criteria and tumor markers quantification.
Methods: Eighty six plasma samples were analyzed by digital PCR using Rare Mutation Assays for E542K, E545K and
H1047R. Mutant cfDNA and tumor markers CA15-3 and CEA were compared with radiographic imaging.
Results: The agreement between PIK3CA mutation status in FFPE samples and circulating tumor DNA (ctDNA) was
moderate (K = 0.591; 95% IC = 0.371–0.811). Restricting the analysis to the metastatic patients, we found a good
agreement between PIK3CA mutation status assessed in liquid and solid biopsy (K = 0.798 95%; IC = 0.586–1). ctDNA
showed serial changes with fluctuations correlating with tumor markers 15.3 and CEA in 7 out of 8 cases with
Pearson correlation coefficients ranging from 0.99 to 0.46 and from 0.99 to 0.38 respectively. Similarly, fluctuations
in the fraction of PIK3CA mutant allele always correlated with changes in lesion size seen on images, although in
two cases it did not correlate with treatment responses as defined by RECIST criteria.
Conclusion: oncogenic mutation quantification in plasma samples can be useful to monitor treatment outcome.
However, it might be limited by tumor heterogeneity in advanced disease and it should be evaluated together
with radiographic imaging.
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Background
Tumor biopsies have been and currently are the
keystone for biomarker testing [1]. However, some limi-
tations of tumor biopsies are still significant, such as
difficulties in obtaining tissue samples, the invasiveness
of the process or tumor heterogeneity, which might
compromise the efficacy of targeted-therapies, based on
a single biopsy [2, 3].
Tissue cells release circulating free DNA (cfDNA) into
the bloodstream. Specifically, tumor-derived DNA (ctDNA)
can be detected in plasma samples by identifying specific
genetic alterations that tumors harbor, using highly sensi-
tive technologies, such as digital PCR (dPCR), with the
advantage that the aforementioned limitations can be
overcome. In addition, quantification of tumor-specific
mutations in liquid biopsies has been shown to correl-
ate with tumor burden and there is growing evidence
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suggesting that ctDNA monitoring can predict treat-
ment outcome [4–9].
At present, tumor response to treatment is commonly
evaluated according to RECIST criteria. However, several
studies have pointed out the limitations that radiology
assessment may have when assessing tumor response,
especially in estrogen receptor (ER) positive breast
cancer patients [10–13].
The PIK3CA gene encodes the p110α catalytic subunit
of PI3K protein, and is mutated in over one-third of breast
cancer cases [14]. Specifically, 40% of hormone dependent
cancers harbor activating mutations in PIK3CA [14–17],
making this gene an attractive candidate for tumor moni-
toring by tumor-specific mutation quantification in
plasma samples. Mutations occur predominantly in the
helical domain (generally E542K and E545K) and the kin-
ase domain (generally H1047R) and account for 70% of all
PIK3CA mutations in breast tumors [14–17]. Hotspot
mutations have been shown to confer oncogenic features
although the prognostic/predictive significance of PIK3CA
mutations remains controversial.
In this study, we compare the clinical information pro-
vided by PIK3CA mutation quantification using array-
based dPCR, in plasma samples from ER positive breast
cancer patients, with tumor markers 15-3 and CEA and
computed tomography (CT) scan assessments.
Methods
Study population
A total of 49 patients with estrogen receptor (ER) positive
breast cancer were prospectively enrolled in the study
after signing the appropriate informed consent. Patients
agree to the publication of anonymized data. The study
protocol was approved by the Hospital Clinico San Carlos
Ethics Committee (internal code 13/383-E). Eligibility cri-
teria comprised the following: women aged between 18
and 80 years with a pathologically confirmed diagnosis in-
vasive breast carcinoma, clinical stage IIB-IIIB or IV and
availability of the archived tissue for genotyping at the
Hospital Clinico San Carlos Biobank. Blood samples were
collected at the beginning of a treatment that the patient
was going to initiate when included in the study. In 43
cases, the tumor specimen collected was the primary
breast tumor; a biopsy of a FFPE metastatic breast cancer
lesion was available in the remaining 6 patients. Informa-
tion concerning demographics, clinicopathological fea-
tures (stage, grade, estrogen and progesterone receptor
status and HER2 status), courses of treatment(s), and vital
status was obtained from the clinical and pathology
reports (Additional file 1).
Laboratory analysis
Eighty six blood samples were collected in BD Vacutai-
ner® CPT™ Cell Preparation Tube with Sodium Heparin
(containing a gel barrier). Hemolyzed samples were
discarded for further analyses. Plasma was derived from
blood samples by centrifugation within 3 hours after
blood extraction. cfDNA was isolated from 3 ml of
plasma using the QIAamp Circulating Nucleic Acid Kit
(Qiagen, Valencia, CA), according to manufacturer’s
instructions. cfDNA was eluted in 35 μL of the supplied
elution buffer. The eluate was reloaded in the column
and eluted by maximum speed centrifugation in order to
increase the amount of cfDNA. Samples were then ana-
lyzed by digital PCR, using Rare Mutation Assays1 for
E542K (AHD2BSD), E545K (AHABHHX) and H1047R
(AHPAVCD) on QuantStudio® 3D Digital PCR System
(Applied Biosystems, South San Francisco, CA). For the
dPCR reaction, 8 ul of cfDNA was mixed with 0.5 ul of the
aforementioned 40X TaqMan assays and 10 ul of 2x
QuantStudio 3D Master Mix, in a 20ul reaction volume.
Subsequently, 15 ul were loaded into QuantStudio 3D
Digital PCR 20 K chips. The cycling conditions were as fol-
lows: initial denaturation at 96 °C for 10 min, followed by
40 cycles at 56 °C for 2 min, and 98 °C for 30s, a step of
72 °C for 10 min and finally samples were kept at 22 °C for
at least 30 min. Chip fluorescence was read twice. Results
were analyzed with QuantStudio® 3D Analysis Suite™ Cloud
Software. The automatic call assignments for each data
cluster where manually adjusted when needed. The ana-
lysis of dPCR data was performed blinded to the clinical
and tumor information by two independent investigators
(AR and ML). Double positive data points (green data
points) where only considered when FAM data points
where visualized. The result of the assay is reported as mu-
tant allele frequency (MAF) which is defined as the ratio of
mutant DNA molecules vs the sum of wild-type (wt) DNA
molecules and mutant DNA molecules. Samples were con-
sidered as positive when MAF was greater than 0.15%. A
wt control DNA was included in every run. All assays were
validated using plasmid DNAs harboring the aforemen-
tioned the PIK3CA mutations (GeneArt, Thermo Fisher
Scientific). Germline wt DNA from healthy donors was
mixed with different mutant allele concentrations (i.e. 1%,
0.5%, 0.1%, 0.05%) in order to estimate the Limit of quanti-
tation (LOQ) and limit of detection (LOD). LOD and LOQ
were calculated based on the standard deviation of the re-
sponse and the slope according to ICH Q2(R1) guideline
(http://www.ich.org/products/guidelines/quality/article/
quality-guidelines.html). The standard deviation of the re-
sponse was calculated based on standard error of the y-
intercept. Additionally, LOD and LOQ were estimated
based on blank measurements. In this case, LOD was
expressed as the average of MAF corresponding to the wt
samples plus three standard deviation and LOQ was the
average of MAF corresponding to the wt samples plus ten
standard deviations. Two replicates were performed for all
patients.
García-Saenz et al. BMC Cancer  (2017) 17:210 Page 2 of 8
For the analyses of FFPE tumor and metastasis sam-
ples, a hemotoxylin and eosin-stained slide was reviewed
by a pathologist to confirm the presence of tumor cells
within the section. Overall, the percentage of tumor cells
in the analyzed samples ranged from 80 to 90%. Subse-
quently, DNA was purified from four 5-mm-thick un-
stained FFPE sections according to the QIAamp DNA
FFPE Tissue Kit (Qiagen, Valencia, CA) protocol.
The identification of PIK3CA mutations on FFPE sam-
ples was performed using COBAS® PIK3CA Mutation
Test (Roche Molecular Systems, Branchburg, NJ). The test
is intended to detect R88Q in exon 1, N345K in exon 4,
C420R in exon 7, E542K, E545X (E545A, E545D,E545G,
and E545K), Q546X (Q546E, Q546K, Q546L, and Q546R)
in exon 9, and M1043I, H1047X (H1047L, H1047R, and
H1047Y), and G1049R in exon 20 when the percent muta-
tion is equal or greater than 5%. PIK3CA mutation status
was further confirmed by the aforementioned TaqMan as-
says on the QuantStudio® 3D Digital PCR System. Con-
flicting samples were further amplified and sequenced.
Primers and conditions used are available upon request.
PCR products were then sequenced on the ABI 3130 gen-
etic analyzer (Applied Biosystems, Foster City, CA), using
the BigDye Terminator v1.1 Cycle Sequencing Reaction
kit (Applied Biosystems, Foster City, CA) following the
manufacturer’s protocol kit.
Serum samples were used to measure the levels of CA
15–3 antigen and CEA (Carcinoembryonic Antigen) using
the high throughput immunoassay analyzer UniCelDxI
800 (Beckman Coulter), according to manufacturer’s in-
structions. In brief, the assay is a two-step sandwich im-
munoassay using direct, chemiluminescent technology.
Response evaluation
Mammogram, ultrasound-based, magnetic resonance
imaging (MRI), computed tomography (CT) and Posi-
tron emission tomography (PET)-CT tumor measure-
ments were obtained, as clinically indicated. The clinical
response was evaluated according to RECIST v1.1 cri-
teria comparing radiological assessments. Complete re-
sponse (CR) was defined as resolution of all palpable,
visible or radiology abnormalities in the breast and re-
gional lymph nodes. Partial response (PR) was defined as
a decrease of ≥30% in the sum of the longest diameter in
the breast and regional lymph nodes. Stable disease (SD)
was assigned to patients who did not meet the criteria
for CR, PR or PD. Clinical Progressive disease (PD) was
defined as an increase of at least 20% in the sum of the
longest diameter in the breast and regional lymph nodes
or progression of other clinical manifestations of disease.
Statistic analysis
Continuous variables are presented as means ± standard
deviations (SD) and discrete variables as proportions.
The weighted quadratic kappa coefficient values and the
corresponding 95% confidence intervals (95% CI) were
estimated in order to measure the strength of agreement
between methodologies. The strength of agreement is
judge to be minor when the К values are between 0.00
and 0.20; fair, 0.21 and 0.40; moderate, 0.41 and 0.60;
good, 0.61 and 0.80 and nearly perfect, 0.81 and 1.00.
Correlation between quantitative variables was evaluated
using the Pearson correlation coefficient. The correlation
among the quantitative variables was evaluated with
simple linear regression analysis. P < 0.05 was considered
to be statistical significance. The statistical analysis was
performed using software R 3.0.1.
Results
Assay performance and agreement between
methodologies
We report data from 49 patients with ER positive breast
cancer undergoing therapy that were prospectively
enrolled in the study. The pathological characteristics
of study population are summarized in Table 1 and
Additional file 1. The source of archival tissue sample
was the primary tumor for 43 (87.8%) patients and
biopsy of a distant metastasis for 6 (12.2%). DNA
Table 1 Clinicopathological features of the study population
Clinicopathologic Characteristics
Age at diagnosis (years)




Histologycal grade (n (%))
I and II 39 (80%)
III 10 (20%)
UICC stage (n (%))
IIB 6 (12%)
IIIA + IIIB 11 (22%)
IV 32 (65%)









Abbreviations: ER estrogen receptor, PR progesterone receptor, HER2 erb-b2
receptor tyrosine kinase 2, UICC Union for International Cancer Control
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isolated from archival-tumor tissue samples was analyzed
to identify PIK3CA somatic mutations. According to
COBAS, among the analyzed tumors, 11 (22.4%) harbored
the mutation H1047R, 5 (10.2%) harbored the E545K and
4 (8.1%) harbored the E542K. These are expected frequen-
cies according to previously published data. Interestingly,
we did not encounter any other less frequent PIK3CA
mutation that could be detected by COBAS methodology.
Subsequently, the three PIK3CA hot spot mutations were
screened in FFPE derived samples using QuantStudio 3D
system. The proportion of observed agreement between
COBAS and QuantStudio3D system when assessing the
PIK3CA mutation status in the archival tumor was 100%
(K = 1) (Additional file 1).
Next, we evaluated the detection sensitivity of TaqMan
assays. For sensitivity assays plasmid carrying E542K,
E545K and H1047R mutations were mixed at different
allele concentrations with wt DNA extracted from per-
ipheral blood cells form healthy donors. Mutant allele
frequencies correlated with the expected mutant allele
frequencies in E542K assay, E545K assay and H1047R
assay (Pearson’s correlation coefficient, 0.9985, 0.9966
and 0.9991 respectively). LOD for E542K, E545K and
H1047R assays were 0.04, 0.05 and 0.03% respectively.
LOQ for E542K, E545K and H1047R assays were 0.13,
0.15 and 0.08% respectively (Additional file 2). Addition-
ally, wt DNA from healthy donors were used to evaluate
the false positive signals. The mean of mutant allele frac-
tion of wt DNA form healthy individuals was 0.01% for
E542K assay, 0.00% for E545K assay and 0.01% for
H1047R.
Finally, we evaluated the agreement between PIK3CA
mutation status of FFPE samples and the matched
plasma sample. The median time between blood collec-
tion at study entry and time that the tumor biopsy was
obtained from the patient was 7 years (range = 0–15
years). Importantly, cfDNA from all plasma samples was
successfully amplified. Representative plots for the three
assays, performed on cfDNA, are displayed in Additional
file 3. The ratio of mutant DNA molecules vs total DNA
molecules ranged from 0.19 to 53.4% in the positive
sample cases. The median of PIK3CA mutated copy
number in positive samples was 1496 copies/ml (range:
63.3–92742).
Overall, we found a moderate agreement between
PIK3CA mutation status in plasma and FFPE tumor
samples (K = 0.591; 95% IC = 0.371–0.811). Specifically,
we found that in 9 samples, the assay failed to detect on
cfDNA the mutation identified in the tumor sample
(data obtained from Additional file 1). However, we did
not find any mutation in the plasma that was not
present in the FFPE sample (sensitivity 55%, specificity
100%, positive predictive value 100%, and negative
predictive value 76%). Restricting the analysis to the
metastatic patients, we found a good agreement between
PIK3CA mutation status assessed in liquid and solid
biopsy (K = 0.798 95%; IC = 0.586-1) (data obtained
Additional file 1). In this case, the cfDNA assay failed to
detect the tumor mutation in 3 samples (sensitivity 77%,
specificity 100%, positive predictive value 100%and nega-
tive predictive value 86%).
Correlation with tumor markers
In 8 breast cancer patients with stage IV disease in
which PIK3CA somatic mutation was identified in both
FFPE and plasma samples, mutant cfDNA and tumor
markers CA15-3 and CEA were quantified in a total of
27 serial plasma samples (Table 2). Circulating tumor
DNA (ctDNA) was identified in 21 of the 27 plasma
samples analyzed. Tumor markers CA15-3 and CEA
levels were evaluated at all-time points in all 8 patients.
Circulating tumor DNA showed serial changes with fluc-
tuations correlating with tumor markers in 7 cases. In
one case (from now on patient 3) changes in PIK3CA
mutation quantification were in the opposite direction
than tumor markers. In patients in which tumor markers
CA15-3 and CEA and PIK3CA mutant DNA fluctuated
in the same way, Pearson correlation coefficients ranged
from 0.99 to 0.46 and from 0.99 to 0.38 respectively
(mean 0.82 for CA 15–3 and 0.79 for CEA).
Concordance between imaging assessments and PIK3CA
mutation quantification in plasma
As an exploratory analysis, in the aforementioned 8
patients we compared the performance of PIK3CA
assays with measurable disease (as defined by RECIST
criteria). The median follow-up was 7.5 months. Overall,
changes in ctDNA were in concordance with treatment
responses observed in imaging. Partial responses were
recognized in two patients (patient 25 and patient 44)
during the follow-up period. In both cases, a reduction
of mutant allele fraction in plasma samples was evidenced
(Additional file 4: Figure S1 and Fig. 1b respectively).
Similarly, progressive disease (PD) was documented in 4
women (patient 44, patient 2, patient 31, patient 3) during
the study. An Increase in PIK3CA mutant allele fraction
reflected progressive disease in 2 patients (patient 2 repre-
sented in Fig. 1a and patient 44 represented in Fig. 1b).
Noteworthy, in one case (patient 31), although H1047R
mutation quantification went down to 0% over the course
of treatment (from 0.19 to 0%; Table 2) correlating with
tumor markers CA15.3 and CEA variations and with the
decrease in size of the pulmonary metastases and the axil-
lary lymphadenopathy, the contrast-enhanced CT scan
from the same period of time demonstrated that the lytic
bone metastases increased in size (Fig. 1c). Similarly, in
case of Patient 3, the hiliar and mediastinal adenopathies
decreased in size from 13 to 8 mm to 7 and 4 mm
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respectively, correlating with E545K mutation quanti-
fication that significantly decreased from 3.07% (CI:
2.71% – 3.465%) to 1.97% (CI: 1.343% – 2.88%) (Table 2)
in the corresponding plasma samples. However, the pul-
monary metastases increased in number and size during
the same period of time correlating with tumor markers
quantification (Fig. 2). Finally, stable disease was docu-
mented in two patients (patient 15 and patient 6) in which
tumor circulating free DNA fluctuated in the same way
that tumor markers fluctuated (Additional file 4: Figure S3
and Figure S4).
Discusion
In this study, we have tested the feasibility of array-
based digital PCR to detect and quantify tumor specific
mutations in plasma samples and we have documented
the correlation between PIK3CA mutation quantification
and tumor responses assessed by RECIST criteria.
Several groups [6, 18–21] have reported the utility of
cfDNA as a source for tumor mutation detection. As de-
scribed by others, we found a good agreement (K =
0.798) between plasma and FFPE samples when asses-
sing PIK3CA mutation status in advanced patients, using
array-based dPCR. However, in our experience the
agreement was lower when early stages patients were in-
cluded. Consistent with this, Oshiro et al have recently
reported that PIK3CA mutations were detected in only
22.7% of serum samples from early-stage breast cancer
patients with tumors harboring a PIK3CA mutation
using array-based dPCR. Of important note, in that
study, the authors proved that the sensitivity of the assay
was 0.01% [22]. In the same way, Bettegowda C et al
have reported ctDNA was detectable in >75% patients
with advanced breast cancer disease whereas the fre-
quency of cases with detectable ctDNA was 50% in early
stages [23]. On the contrary, other researchers have re-
ported a high agreement between liquid and solid biopsy
Table 2 ctDNA and tumor markers measurements in 8 breast cancer patients with stage IV disease
Patient Tracked mutation Sample Target/Total mutated copies/mL CA 15.3 (U/ml) CEA (ng/ml) Figure
25 H1047R March 07 2014 18.36% 54398 97 27 Additional file 4: Figure S1
Oct 13 2014 0.11% 12.1 32.8 7.1
Nov 03 2014 0% 0 32.3 7.5
44 H1047R Aug 29 2014 1.78% 310.5 126 1.6 Fig. 1b
Sep 17 2014 1.85% 975 997.2 5.2
Oct 23 2014 2.08% 1203.2 1219 11.6
Nov 19 2014 0.81% 102.9 487.3 4.8
15 H1047R Feb 18 2014 0.36% 24.7 68.9 4.7 Additional file 4: Figure S3
May 29 2014 0.32% 30.6 58.6 4.3
Aug 27 2014 0.03% 25.6 39.4 3.3
2 H1047R Dec 03 2013 2.39% 149.6 96.8 5.7 Fig. 1a
Jan 02 2014 3.93% 77.3 91.6 12.7
Jan 30 2014 4.39% 3082.1 100.6 13.9
March 03 2014 9.61% 3629.3 138.1 19.8
31 H1047R March 27 2014 0.19% 13.5 89.3 22.1 Fig. 1c
Aug 29 2014 0% 0 30.7 6.2
Oct 02 2014 0% 0 28.8 5.1
Nov 03 2014 0% 0 17.5 4.4
11 E545K March 06 2014 27.19% 9274.2 86 108 Additional file 4: Figure S2
April 09 2014 6.61% 235.9 66 86
3 E545K Dec 02 2013 4.23% 412.5 57.6 2.8 Fig. 2
March 12 2014 3.07% 1839.5 60.8 3
Sep 10 2014 1.97% 165.1 114.6 15.1
Dec 15 2014 0.76% 143.5 179.5 9
6 E542K Feb 10 2014 0.24% 63.30 115.6 3.9 Additional file 4: Figure S4
Apr 04 2014 0% 0 88.5 2.9
Sep 05 2014 0% 0 45 1.7
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a c
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Fig. 1 Panel (A) shows plasma levels of H1047R PIK3CA mutation (%) on cfDNA quantified by dPCR and CEA (ng/ml) tumor marker across four
time points (months) (Pearson correlation coefficient =0.92) from patient 2, PD = progressive disease. Panel (B) shows plasma levels of H1047R
PIK3CA mutation (%) on cfDNA across four time points (months). Disease status as ascertained on a CT-scan at two time points is marked with a
discontinuous line. The use of adryamicine based chemotherapy is indicated by gray shading. As shown, PIK3CA mutation quantification increased
until October when the patient 44 was diagnosed as having a progressive disease (PD). Subsequently, the patient received a different line of
palliative treatment. PIK3CA mutation significantly decreased from 2.08% (CI 1.768% – 2.429%) to 0.81% (0.487% – 1.342%) correlating with the
partial response (PR) assessed by CT-scan. Panel (C) shows the plasma levels of tumor markers 15–3 (U/ml) and CEA (ng/ml) and CT-scans
showing the bone metastasis, lung metastases and the axillary adenopathy from patient 31. In this case the H1047R mutation quantification went
down to 0% over the course of treatment (from 0.19 to 0%) correlating with tumor markers, the visceral metastases (white arrow) and the
adenopathies (circle) although the bone metastasis increased significantly in size (white arrow)
Fig. 2 E545K assay scatter plots from patient of Patient 3 plasma samples and the corresponding CT scan images showing the hilar and mediastinal
adenophaties and the lung metastases (arrows and circles). The asterisk indicates the lung hilum vessels
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for PIK3CA mutation status assessment in early stages
using droplet digital PCR [19]. Nevertheless, the sample
size of our study was limited and larger sized cohorts
are needed to clarify this issue. To our knowledge, there
is no data comparing the aforementioned methodologies
(droplet vs array). Such studies would be of particular
interest in order to determine the best strategy for bio-
marker testing to guide targeted cancer therapies using
liquid biopsy.
The evaluation of tumor response to treatment that
identifies patients early on that do not benefit from ther-
apies remains a public health challenge. The capacity of
serial monitoring of ctDNA to track tumor burden has
been previously addressed by several researchers [6, 13, 24].
In this way, Dawson SJ et al analyzed PIK3CA mutation
quantification in 13 cases [6]. According to the authors,
PIK3CA mutation quantification correlated with changes
in tumor burden. Similarly, we found that in 6 out of 8
cases the level of PIK3CA mutations correlated with treat-
ment responses according to RECIST criteria. In the two
remaining cases, the discordance could be reflective of
tumor evolution. Indeed, the radiology evaluation of the
disease revealed a different sensitivity of the metastatic le-
sions to treatment, highlighting the issue of heterogeneity
within advance disease. Similarly, Higgins [18] et al re-
ported a 27.5% discordance among 51 patients with recur-
rent metastatic disease prospectively tested by BEAMing in
blood compared with standard sequencing of archival tis-
sue. Yet, our findings were consistent with responses seen
on imaging as we could impute the lesions that most prob-
ably harbored the PIK3CA mutation. It is well known that
breast cancer is a heterogeneous disease and that molecular
profile of cancer can change over time [25, 26]. This fact
might limit usefulness of ctDNA to monitor response to
treatment, especially when the mutation tracked is not
targeted by therapy.
In any case, our results suggest that changes in mutant
allele fraction in liquid biopsy should be analyzed
together with imaging data in order to make mutation
analysis informative.
Conclusions
In this study, we have shown that fluctuations in the frac-
tion of PIK3CA mutant allele always correlated with
changes in lesion size seen on images, although not always
with treatment responses, as defined by RECIST criteria.
Our findings suggest that information provided by onco-
genic mutation quantification in plasma samples could be
limited by tumor heterogeneity in advanced disease and
should be evaluated together with radiographic imaging.
Endnotes
1For Research Use Only. Not for use in diagnostic
procedures.
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Additional file 1: Clinical and pathological variables. (XLSX 16 kb)
Additional file 2: Limit of detection and limit of quantification
estimation according to ICH guidelines. (XLSX 30 kb)
Additional file 3: Performance of PIK3CA assays on cfDNA. Data from
sample chips are displayed in a scatter plot based on color of FAM and
VIC events. Plots A, C and E correspond to a negative samples. Plots B, D
and F correspond to positive samples for the H1047R, E545K and E542K
mutation respectively. The mutation is labeled with FAM (blue data
points) whereas wild-type is labeled with VIC (red data points). Yellow
cluster represent the no amplification cluster. (PPTX 153 kb)
Additional file 4: Serial plasma PIK3CA mutation levels and treatment
outcome, assessed according to RECIST criteria v.1.1. SD = stable disease,
PR = partial response, PD = progressive disease of individual cases. (PPTX
78 kb)
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